| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/22/2001 | DE19938671A1 New nucleic acid encoding cerebral sphingomyelinase, useful e.g. for diagnosis and treatment of inflammation and cancer |
| 02/22/2001 | DE19937837A1 New human gene OLFXX, encoding an olfactory receptor, useful for diagnosis, treatment and development of pharmaceuticals |
| 02/22/2001 | DE19937361A1 Orale Darreichungsform The oral dosage form |
| 02/22/2001 | DE19936744A1 Phagozytenmodulatoren (insbesondere Phagozytenaktivatoren) zur Behandlung und/oder Prophylaxe thrombotischer, atherothrombotischer und/oder hämostaseologischer Erkrankungen Phagozytenmodulatoren (especially Phagozytenaktivatoren) for the treatment and / or prophylaxis of thrombotic, atherothrombotic and / or blood coagulation disorders |
| 02/22/2001 | DE19910108C2 Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie Cells, which co-express an amyloid precursor protein and an alpha-secretase, a test method for identifying alpha-secretase active substances as well as one further for identifying secretases, a test method for determining the susceptibility to Alzheimer's disease, and use of nucleic acids encoding an alpha-secretase , for gene therapy |
| 02/22/2001 | CA2698353A1 Pharmaceutical compounds |
| 02/22/2001 | CA2464845A1 Hematopoietic regulatory factors and methods of use thereof |
| 02/22/2001 | CA2452118A1 Pharmaceutical compositions for oral and topical administration |
| 02/22/2001 | CA2414171A1 Partial agonists at the glycine modulatory site of the nmda receptor for treating cognitive dysfunction |
| 02/22/2001 | CA2385487A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | CA2385475A1 18 human secreted proteins |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2383922A1 Cytokine receptor common gamma chain like |
| 02/22/2001 | CA2383691A1 Human tumor necrosis factor receptor tr16 |
| 02/22/2001 | CA2383264A1 Binary encoded sequence tags |
| 02/22/2001 | CA2383154A1 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | CA2382251A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382095A1 Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof |
| 02/22/2001 | CA2382056A1 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1 |
| 02/22/2001 | CA2382048A1 Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| 02/22/2001 | CA2382019A1 Isomerase proteins |
| 02/22/2001 | CA2382018A1 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2382015A1 Membrane associated proteins |
| 02/22/2001 | CA2381985A1 Vegf-d and angiogenic use thereof |
| 02/22/2001 | CA2381981A1 Orally active peptides that prevent cell damage and death |
| 02/22/2001 | CA2381979A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | CA2381863A1 Novel transcription factor, bp1 |
| 02/22/2001 | CA2381798A1 Method for treatment of .beta.-hemoglobinopathies |
| 02/22/2001 | CA2381794A1 Helical cytokine zalpha48 |
| 02/22/2001 | CA2381780A1 Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
| 02/22/2001 | CA2381712A1 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 02/22/2001 | CA2381409A1 Nitric ester derivatives |
| 02/22/2001 | CA2380979A1 Inhibitors of the lectin complement pathway (lcp) and their use |
| 02/22/2001 | CA2380966A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras |
| 02/22/2001 | CA2380953A1 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | CA2380888A1 Treatment of metastatic disease |
| 02/22/2001 | CA2380883A1 Microparticles for pulmonary administration |
| 02/22/2001 | CA2380820A1 Neurotherapeutic clavulanate composition and method |
| 02/22/2001 | CA2380817A1 Cell adhesion inhibitors |
| 02/22/2001 | CA2380753A1 Use of proteinase inhibitor in order to inhibit the cleavage of growth factor precursor |
| 02/22/2001 | CA2380653A1 Mycophenolate mofetil in association with peg-ifn-.alpha. |
| 02/22/2001 | CA2380642A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | CA2380635A1 Tgf-.alpha. polypeptides, functional fragments and methods of use therefor |
| 02/22/2001 | CA2379940A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 02/22/2001 | CA2379647A1 Melanocortin metallopeptide constructs, combinatorial libraries and applications |
| 02/22/2001 | CA2377662A1 Novel protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | CA2377415A1 An oral administration form |
| 02/22/2001 | CA2346127A1 Novel deoxyribonuclease, gene encoding the same and use thereof |
| 02/21/2001 | EP1077260A1 Parvovirus NS1 variants |
| 02/21/2001 | EP1077259A1 NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF |
| 02/21/2001 | EP1077218A2 Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors |
| 02/21/2001 | EP1077217A2 Neuroactive peptides and their use |
| 02/21/2001 | EP1077070A2 Oral drug delivery compositions |
| 02/21/2001 | EP1077069A1 Preventives/remedies for hepatic cirrhosis |
| 02/21/2001 | EP1077068A1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 02/21/2001 | EP1076711A2 Human apoptosis associated proteins |
| 02/21/2001 | EP1076710A2 Factors affecting tumor necrosis factor receptor releasing enzyme activity |
| 02/21/2001 | EP1076704A1 Il-2 selective agonists and antagonists |
| 02/21/2001 | EP1076703A2 Il-17 homologous polypeptides and therapeutic uses thereof |
| 02/21/2001 | EP1076702A1 Human protease associated proteins |
| 02/21/2001 | EP1076701A1 Antibodies to cd23, derivatives thereof, and their therapeutic uses |
| 02/21/2001 | EP1076700A2 Human nucleic acid sequences obtained from pancreas tumor tissue |
| 02/21/2001 | EP1076699A2 Method of inhibiting osteoclast activity |
| 02/21/2001 | EP1076698A2 Transgenic plant-derived human blood coagulation factors |
| 02/21/2001 | EP1076697A2 Semaphorin polypeptides |
| 02/21/2001 | EP1076696A2 Human receptor molecules |
| 02/21/2001 | EP1076689A1 Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same |
| 02/21/2001 | EP1076663A1 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors |
| 02/21/2001 | EP1076662A2 Polyepitope carrier protein |
| 02/21/2001 | EP1076645A1 Process for the preparation of methyl(2s)-2-[(3r)-3-(n-[tert-butyloxycarbonyl]-amino) -2-oxopyrr olidin-1-yl]propionate |
| 02/21/2001 | EP1076569A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| 02/21/2001 | EP1076565A1 Indolicidin analogs and methods of using same |
| 02/21/2001 | EP1076563A1 Dipeptide caspase inhibitors and the use thereof |
| 02/21/2001 | EP1076561A2 Combination therapy for the treatment of tumors |
| 02/21/2001 | EP0948525B1 Cyclic peptide derivatives |
| 02/21/2001 | EP0871470A4 Haemopoietic growth factor antagonists and uses therefor |
| 02/21/2001 | EP0784683B1 Tie-2 ligands, methods of making and uses thereof |
| 02/21/2001 | EP0776175A4 Therapeutic homeopathic dilutions of growth factors and methods of their use |
| 02/21/2001 | EP0725825B1 Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
| 02/21/2001 | EP0652968B1 Defective adenoviruses |
| 02/21/2001 | EP0580635B2 Modified plant viruses as vectors |
| 02/21/2001 | EP0527852B2 Method and compositions for treating injury |
| 02/21/2001 | EP0526452B1 Hybrid immunoglobulins |
| 02/21/2001 | CN1284996A Tumor antigen protein, gene thereof, and utilization thereof |
| 02/21/2001 | CN1284995A Tissue cement proteins from rhipicephalus appendiculatus |
| 02/21/2001 | CN1284994A Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 02/21/2001 | CN1284965A Novel surface protein of i (neisseria meningitidis) |
| 02/21/2001 | CN1284962A Isolated nucleic acid molecules which encode TAGE molecules, and uses thereof |
| 02/21/2001 | CN1284885A Vaccine |
| 02/21/2001 | CN1284884A 疫苗 Vaccine |
| 02/21/2001 | CN1284882A Beta-lipotropin and uses thereof |
| 02/21/2001 | CN1284881A Heparin cofactor II preparations and process for producing the same |
| 02/21/2001 | CN1284876A Insoluble compositions for controlling blood glucose |
| 02/21/2001 | CN1284860A Microparticles and their therapeutic or diagnostic use |
| 02/21/2001 | CN1284563A Recombined carrier carrying human liver cell growth factor gene and its application in treating ischemic diseases |
| 02/21/2001 | CN1284381A Recombined human interferon alpha gel preparation and its production process |
| 02/21/2001 | CN1284380A Application of bone morphogenesis protein (BMP) as medicine for acute aplastic anemia |
| 02/21/2001 | CN1284368A Method of extracting activated hemagglutination factor and inhibitor component (ATI) from tea |
| 02/21/2001 | CN1284327A Composition for making unstable material of oxygen stabilize |